This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This continuously growing pipeline of pharmaceutical drug products has inadvertently led to an increase in the demand for their associated primary packaging and Secondary Packaging solutions. . 3] Some of the advantages offered by pharmaceutical secondary packaging have been depicted below.
In today’s global landscape, sustainability has emerged as a pivotal concern across various sectors including the pharmaceuticalpackaging industry. What is Sustainable Packaging / Green Packaging? The following figure presents the raw materials used by the sustainable packagingcompanies.
The company developing drug product through such an intense process, use to consider container closure system only for packaging of the product. [1] Thereafter, high quality standards were set for packaging and closure of such containers by the regulatory bodies. [2] Web: [link]. LinkedIn: [link]. Twitter: [link]. Quora: [link].
The Guidance applies to all member companies of EFPIA and IFPMA, but also acts as useful guidance for all pharmaceuticalcompanies as to how the authorities will interpret the legislative provisions to social media channels. However, the involvement of the company should always be stated.
Navigating these regulatory challenges is essential to ensure compliance, maintain trust, and effectively communicate the benefits and risks of pharmaceutical products. In this blog post, we will explore best practices for pharmaceuticalcompanies to navigate the complex landscape of regulatory challenges in marketing.
iSpeak Blog. Applying what has been learned over the last three years to update pharmaceuticalcompanies’ approaches to development and implementation is key as the industry crafts its strategies in an increasingly digital and global environment. 2022 ISPE Annual Meeting: Transform, Collaborate, & Innovate for the Path Forward.
This article reviews the earliest protype that we know of for a LEED manufacturing facility, presents a real-world case study of a pharmaceutical manufacturing facility achieving LEED Gold, and describes sustainability certifications that go beyond LEED.
The recent legislative reform proposals put forward by the European Commission (EC) have sparked significant discontent among pharmaceuticalcompanies. While a handful of incentives are offered by the reform package, they are overshadowed by the potential drawbacks for the innovative sector.
Navigating these regulatory challenges is essential to ensure compliance, maintain trust, and effectively communicate the benefits and risks of pharmaceutical products. In this blog post, we will explore best practices for pharmaceuticalcompanies to navigate the complex landscape of regulatory challenges in marketing.
Additionally, the fill finish manufacturing of biologics is a critical step in the production of biopharmaceuticals as it requires well-equipped facilities with adequate sterile filling and packaging lines to ensure sterility of the product while filling into the final containers.
The physicians provided their patients with cutting-edge therapies quite often found in the literature and not necessarily in the package insert. He also had the drug’s package insert. Unfortunately, both the vials and the package insert were written entirely in the “Swiss French” language. The hospital was ahead of its time.
GLP-1 receptor agonist market have captured the attention of both large and small pharmaceuticalcompanies, for more than a decade. per package in the US. However, after a decade-long dribble of GLP-1 drugs and the recent approval of obesity drugs, the domain has gained significant attention.
If commercial, accessibility of cGMP API for proof of concept (POC) studies is much more possible in bulk in the open market, and may already be packaged in a suitable dosage form or strength for human trials.
The support from venture capitalists and big pharmaceuticalcompanies will continue to drive the development of circular RNA therapeutics and RNA therapeutics market growth over the forecast period. Considering the potential of these therapies, several industry stakeholders are actively engaging in the development of such therapeutics.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content